CN112955446B - 6-氟-2-甲基苯并[d]噻唑-5-基化合物 - Google Patents

6-氟-2-甲基苯并[d]噻唑-5-基化合物 Download PDF

Info

Publication number
CN112955446B
CN112955446B CN201980062923.0A CN201980062923A CN112955446B CN 112955446 B CN112955446 B CN 112955446B CN 201980062923 A CN201980062923 A CN 201980062923A CN 112955446 B CN112955446 B CN 112955446B
Authority
CN
China
Prior art keywords
compound
mmol
stirred
pharmaceutically acceptable
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980062923.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112955446A (zh
Inventor
N·J·F·德雷福斯
J·E·洛佩斯
L·L·小温纳罗斯基
E·M·沃利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN112955446A publication Critical patent/CN112955446A/zh
Application granted granted Critical
Publication of CN112955446B publication Critical patent/CN112955446B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201980062923.0A 2018-09-26 2019-09-19 6-氟-2-甲基苯并[d]噻唑-5-基化合物 Active CN112955446B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736588P 2018-09-26 2018-09-26
US62/736,588 2018-09-26
PCT/US2019/051820 WO2020068530A1 (en) 2018-09-26 2019-09-19 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

Publications (2)

Publication Number Publication Date
CN112955446A CN112955446A (zh) 2021-06-11
CN112955446B true CN112955446B (zh) 2024-07-12

Family

ID=68085016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980062923.0A Active CN112955446B (zh) 2018-09-26 2019-09-19 6-氟-2-甲基苯并[d]噻唑-5-基化合物

Country Status (8)

Country Link
US (2) US10752632B2 (enExample)
EP (1) EP3856739A1 (enExample)
JP (2) JP7081047B2 (enExample)
CN (1) CN112955446B (enExample)
AR (1) AR116428A1 (enExample)
CA (1) CA3113968C (enExample)
TW (1) TWI716107B (enExample)
WO (1) WO2020068530A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI716107B (zh) * 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
US20240043418A1 (en) * 2020-03-26 2024-02-08 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
WO2024081775A1 (en) 2022-10-14 2024-04-18 Eli Lilly And Company Synthesis of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1218466A (zh) * 1996-05-10 1999-06-02 詹森药业有限公司 作为多巴胺d4受体拮抗剂的2,4－二氨基嘧啶衍生物
WO2016030443A1 (en) * 2014-08-28 2016-03-03 Asceneuron Sa Glycosidase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
HUE043398T2 (hu) 2013-03-14 2019-08-28 Merck Patent Gmbh Glikozidáz inhibítorok
WO2017071636A1 (zh) 2015-10-30 2017-05-04 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
WO2017106254A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
FR3046053B1 (fr) 2015-12-24 2017-12-22 Sagem Defense Securite Module de pied pour une structure d'exosquelette
MA43677A (fr) * 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
CA3044762A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
JP2020503298A (ja) * 2016-12-16 2020-01-30 ヤンセン ファーマシューティカ エヌ．ベー． 単環式ｏｇａ阻害剤化合物
AR110747A1 (es) 2017-01-27 2019-05-02 Lilly Co Eli Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物
TWI716107B (zh) * 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1218466A (zh) * 1996-05-10 1999-06-02 詹森药业有限公司 作为多巴胺d4受体拮抗剂的2,4－二氨基嘧啶衍生物
WO2016030443A1 (en) * 2014-08-28 2016-03-03 Asceneuron Sa Glycosidase inhibitors

Also Published As

Publication number Publication date
CA3113968A1 (en) 2020-04-02
EP3856739A1 (en) 2021-08-04
JP7081047B2 (ja) 2022-06-06
US10836773B1 (en) 2020-11-17
US10752632B2 (en) 2020-08-25
JP7560511B2 (ja) 2024-10-02
WO2020068530A1 (en) 2020-04-02
AR116428A1 (es) 2021-05-05
JP2022502389A (ja) 2022-01-11
JP2022116171A (ja) 2022-08-09
CA3113968C (en) 2023-08-01
TWI716107B (zh) 2021-01-11
CN112955446A (zh) 2021-06-11
US20200354370A1 (en) 2020-11-12
TW202026293A (zh) 2020-07-16
US20200095254A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
EP3190889B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
JP6106745B2 (ja) （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
JP2014526453A (ja) ピリジン化合物およびそれらの使用
JP7560511B2 (ja) ６－フルオロ－２－メチルベンゾ［ｄ］チアゾール－５－イル化合物
CN109890824B (zh) 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
WO2014096212A1 (en) NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
EP3679039A1 (en) Tyrosine analogues derivatives as rho- kinase inhibitors
CN111699188B (zh) [1,2,4]三唑并[4,3-a]吡嗪-8-酮衍生物
JP6850396B2 (ja) ［１，２，４］トリアゾロ［４，３−ａ］ピラジン−６（５ｈ）−オン誘導体
CN112469476B (zh) 5-甲基-4-氟-噻唑-2-基化合物
EP3810275B1 (en) 2,3-dihydrofuro[2,3-b]pyridine compounds
KR20070022753A (ko) 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
FR2884824A1 (fr) Derives de 1h-pyrimido[4,5-b]indole, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant